Yes, ISIS claimed responsibility ... He also owned his own plane and made a lot …
There's no ISIS. There's nobody else there ... So we should not be really surprised at this, but we should take stock of …
As human beings it can sometimes be difficult for us to see the good in a bad situation. In the biotech sector, where …
Isis Pharmaceuticals, Inc. (ISIS) was a big mover last session, as the company saw its shares soar nearly 11% on the day. The move came on the back of a licensing deal with Johnson & Johnson worth up to $835 million. This led to far …
MarketWatch named Isis one of five drug stocks that may benefit from more ALS awareness in a story last week. That may also be helping to fuel the stock's run. And Isis has a link on the community section of its own Web site devoted …
celebrating some key milestones and taking stock of the long road ahead. Add ISIS as an interest to stay up to date on the latest ISIS news, video, and analysis from ABC News. After two days of coalition-wide meetings, U.S. Special …
Shares of Isis Pharmaceuticals Inc. rose 10 percent yesterday after the drug maker said it had received a milestone payment from Boehringer Ingelheim about its genetic treatment for Crohn's disease. The company, which is based in …
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other …
Intraday, BSX stock broke through some recent resistance at $13.75, before closing out the day at $13.81. The agreement states that JNJ will pay ISIS up to $835 million to allow Janssen the option to license three of these drugs for …
Ionis’ decision is understandable, especially given the publicly-traded company appears as “ISIS” on stock exchange tickers; not exactly an attractive target for potential investors. “Our goal is to create medicines that will save patients’ …